Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Decreases By 13.5%

Krystal Biotech, Inc. (NASDAQ:KRYS) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 2,760,000 shares, a decline of 13.5% from the February 13th total of 3,190,000 shares. Based on an average trading volume of 278,600 shares, the days-to-cover ratio is currently 9.9 days. Currently, 11.2% of the shares of the stock are short sold.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on KRYS. Jefferies Financial Group assumed coverage on Krystal Biotech in a report on Wednesday, March 5th. They set a “buy” rating and a $245.00 price target on the stock. Chardan Capital boosted their target price on shares of Krystal Biotech from $212.00 to $218.00 and gave the stock a “buy” rating in a report on Thursday, February 20th. Cantor Fitzgerald restated an “overweight” rating and issued a $215.00 price target on shares of Krystal Biotech in a research report on Thursday, February 20th. HC Wainwright reiterated a “buy” rating and set a $221.00 price target on shares of Krystal Biotech in a report on Friday, February 28th. Finally, Citigroup raised their target price on Krystal Biotech from $206.00 to $215.00 and gave the stock a “neutral” rating in a research report on Thursday, February 20th. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus price target of $220.00.

Krystal Biotech Trading Down 0.3 %

Shares of KRYS stock opened at $188.61 on Friday. The stock has a market cap of $5.43 billion, a price-to-earnings ratio of 63.08 and a beta of 0.87. The stock has a 50-day moving average of $165.98 and a 200-day moving average of $173.80. Krystal Biotech has a 1-year low of $141.72 and a 1-year high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last announced its earnings results on Monday, February 24th. The company reported $1.52 EPS for the quarter, beating the consensus estimate of $1.29 by $0.23. Krystal Biotech had a return on equity of 11.41% and a net margin of 30.69%. The company had revenue of $91.10 million for the quarter, compared to analyst estimates of $91.35 million. During the same quarter in the prior year, the company earned $0.30 EPS. The firm’s revenue for the quarter was up 116.4% compared to the same quarter last year. Sell-side analysts forecast that Krystal Biotech will post 6.14 earnings per share for the current year.

Insiders Place Their Bets

In related news, CAO Kathryn Romano sold 750 shares of the stock in a transaction that occurred on Thursday, February 27th. The shares were sold at an average price of $175.22, for a total value of $131,415.00. Following the completion of the transaction, the chief accounting officer now owns 12,604 shares of the company’s stock, valued at $2,208,472.88. This represents a 5.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $177.79, for a total transaction of $4,444,750.00. Following the sale, the insider now directly owns 1,463,711 shares in the company, valued at approximately $260,233,178.69. The trade was a 1.68 % decrease in their position. The disclosure for this sale can be found here. Insiders own 14.10% of the company’s stock.

Institutional Investors Weigh In On Krystal Biotech

Several institutional investors and hedge funds have recently made changes to their positions in the business. FMR LLC boosted its position in shares of Krystal Biotech by 0.5% during the 4th quarter. FMR LLC now owns 4,314,014 shares of the company’s stock valued at $675,833,000 after purchasing an additional 21,133 shares in the last quarter. Vanguard Group Inc. boosted its position in shares of Krystal Biotech by 1.0% during the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company’s stock valued at $450,938,000 after purchasing an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC boosted its position in shares of Krystal Biotech by 0.3% during the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company’s stock valued at $411,831,000 after purchasing an additional 6,600 shares in the last quarter. State Street Corp boosted its position in shares of Krystal Biotech by 9.0% during the 3rd quarter. State Street Corp now owns 1,452,811 shares of the company’s stock valued at $264,455,000 after purchasing an additional 119,936 shares in the last quarter. Finally, Geode Capital Management LLC boosted its position in shares of Krystal Biotech by 2.0% during the 3rd quarter. Geode Capital Management LLC now owns 591,631 shares of the company’s stock valued at $107,714,000 after purchasing an additional 11,411 shares in the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Company Profile

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).